Unit 1 Drugs: Name, Class, Mechanism of action, Therapeutic uses, and Toxicity Flashcards

1
Q

Combinations: ABVD

A

Adriamycin (doxorubicin), Bleomycin, Vinblastine, Dacarbazine.

Treats: First Line for Hodgkins Lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Combinations: CHOP

A

Cycloposphamide, hydroxydoxorubicin, vincristine (Oncovine), prednisone.

Treats: Non-Hodgkins lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Combinations: MOPP

A

Mechlorethamine, vincristine (Oncovine), procarbazine, prednisone.

Treats: Older treatment for Hodgkins Lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Combinations: CMF

A

Cycloposphamide, methotrexate, 5-fluorouriacil

treats: older tx for Breast cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Combinations: FEC

A

5-fluorouracil, epirubicin, Cycloposphamide

Treats: Breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Name the types of anticancer drugs

A
alkylating agents
antimetabolites
DNA Intercalating agents
Microtubule inhibitors
topoisomerase inhibitors
hormones and their antagonists
miscellaneous agents
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

General Mech. of Action for Alkylating Agents

A

Produce strong electrophiles via the formation of carbonium or ethyleneimonium ion intermediates, which form COVALENT linkages by alkylation of nucleophilic parts present in DNA.

(N7 of Guanine typically)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Alkylating agents have extensive toxicity and substantial potential for resistance.

A

Yes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the classes of alkylating agents?

A

Nitrogen mustards
Nitrosoureas
Triazenes
Platinum analogs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the Nitrogen Mustards?

A

Nitrogen mustards are a class of Alkylating agents.

Spontaneously activated in plasma, or via enzymes in liver.

Drugs:
Mechlorethamine
Cyclophosphamide and Ifosamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Mechlorethamine

A

Alkylating Agent.
Class: Nitrogen Mustard
Mechanism of action: COVALENTLY bind to DNA via alkylation of nucleophilic portions of DNA.
Therapeutic Uses: Hodgkin’s (part of MOPP), also topically for cutaneous t-cell lymphoma
Toxicity: GI and Bone Marrow (myelosuppression)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Cyclophosphamide and Ifosamide

A

Alkylating Agent.
Class: Nitrogen Mustard
Mechanism of action: ProDrugs converted to active metabolites via hepatic cytochrome p450 enzymes. COVALENTLY bind to DNA via alkylation of nucleophilic portions of DNA.

Therapeutic Uses:
Cyclophosphamide: most common alkylating agent used. singly or in combination for acute and chronic lymphocytic leukemia, Non-Hodgkin’s, breast, lung, and ovarian cancers.
Ifosfamide: sarcoma and testicular cancer

Toxicity: GI, Bone Marrow Suppression, HEMORRHAGIC CYSTITIS (local irritation of bladder due to toxic metabolite in urine ACROLINE. Give MESNA to counter acroline).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the Nitrosoureas?

A

Nitrosoureas are a class of Alkylating agents.

They are highly lipophilic and can cross the blood brain barrier.

Drugs:
Carmustine and Lomustine

Nitro’sUrea is -mustine, and he’s oily/greasy too(lipophilic).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Carmustine and Lomustine

A

Alkylating Agent
Class: Nirtosoureas

COVALENTLY bind to DNA via alkylation of nucleophilic portions of DNA. Highly lipophilic, can cross the blood brain barrier, yo.

Therapeutic uses: Brain tumors

Toxicity: 
profound myelosuppression
severe GI
RENAL TOXICITY 
PULMONARY FIBROSIS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the Triazenes?

A

Triazenes are a class of Alkylating agents.

Drugs:
Dacarbazine: prodrug that requires metabolism by cytochromes in liver for activation.
Temozolomide: undergoes nonenzymatic conversion at physiological pH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Dacarbazine and Temozolomide

A

Alkylating agent
Class: Triazenes

COVALENTLY bind to DNA via alkylation of nucleophilic portions of DNA.
Dacarbazine: prodrug that requires metabolism by cytochromes in liver for activation. (IV administration)
Temozolomide: undergoes nonenzymatic conversion at physiological pH (oral administration)

Therapeutic uses:
Dacarbazine: part of ABVD for Hodgkin’s, also used for malignant melanoma
Temozolomide: malignant gliomas (standard of care + radiation)

Toxicity:
GI
Myelosuppression (neutropenia and thrombocytopenia)
FLU-LIKE SYMPTOMS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are Platinum Analogs?

A

Platinum analogs are a class of Alkylating agents.

Only inorganic drugs.

Mech of action: Covalently bind to nucleophilic sites on DNA (NOTE: THEY DO NOT FORM CARBONIUM ION INTERMEDIATES). They react with water to form positively charged intermediates that react with guanine forming an intra- and interstrand cross-links.

Drugs:
Cisplatin
Carboplatin
Oxaliplatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Cisplatin,

A

Alkylating agent
Class: Platinum analog

Mech of action: Covalently bind to nucleophilic sites on DNA (NOTE: THEY DO NOT FORM CARBONIUM ION INTERMEDIATES). They react with water to form positively charged intermediates that react with guanine forming an intra- and interstrand cross-links.

Therapeutic uses:
wide range of neoplasms. Testicular, ovarian, cervical, and bladder cancers. Head and neck cancers, lung carcinoma. Often used in combinations.

Toxicity:
Cisplatin: RENAL TOXICITY (RENAL TUBULAR NECROSIS) (a dose limiting toxicity).
ototoxicity (hearing loss)
severe GI
PERIPHERAL MOTOR AND SENSORY NEUROPATHY AT HIGH DOSES
mild/moderate myelosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Carboplatin

A

Alkylating agent
Class: Platinum analog

Mech of action: Covalently bind to nucleophilic sites on DNA (NOTE: THEY DO NOT FORM CARBONIUM ION INTERMEDIATES). They react with water to form positively charged intermediates that react with guanine forming an intra- and interstrand cross-links.

Therapeutic uses:
ovarian cancer

Toxicity:
Myelosuppression (thrombocytopenia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Oxaliplatin

A

Alkylating agent
Class: Platinum analog

Mech of action: Covalently bind to nucleophilic sites on DNA (NOTE: THEY DO NOT FORM CARBONIUM ION INTERMEDIATES). They react with water to form positively charged intermediates that react with guanine forming an intra- and interstrand cross-links.

Therapeutic uses:
gastric and colorectal cancer

Toxicity:
PERIPHERAL SENSORY NEUROPATHY (cold induced acute peripheral neuropathy)
neutropenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the antimetaboiltes?

A

Structural analogs of Folic acid or of the Purine/Pyrimidine bases.

Mech of Action: they inhibit enzymes required for purine/ pyrimidine synthesis or compete with them in DNA /RNA synthesis. They are therefore Cell Cycle Specific Drugs. (inhibit S phase)

Drugs:
Folate analogs: Methotrexate and Pemetrexed
Pyrimidine analogs: 5-fluorouracil, Cytarabine, Gemcitabine
Purine analog: 6-Mercaptopurine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Methotrexate

A

Antimetabolite
Class: Folate analog

Mech of action:
folic acid antagonist that inhibits dihydrofolate reductase (DHFR). Therefore, thymidine and purine synthesis is disrupted.

Therapeutic use:

  • childhood ALL and Choriocarcinoma
  • combination therapy for Burkitt’s lymphoma and breast, ovary, head & neck, and bladder carcinomas.
  • Intrathecal use for meningeal leukemia and meningeal metastasis of many cancers
  • osteosarcoma

Toxicity: (can be countered with administration of activated form of folic acid called LEUCOVORIN)

myleosuppression, spontaneous hemorrhage
GI
RENAL TOXICITY at high doses. (crystalize in urine and cause renal damage)
HEPATOTOXICITY (long term risk of fibrosis & cirrhosis
defective gamete formation (and spontaneous abortion)

Mech of resistance:
reduced drug uptake
increased production of DHFR
decreased affinity of DHFR for drug.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

5-fluoruracil

A

Antimetabolite
Class: Pyramidine analog

NB: Given IV due to severe GI toxicity and rapid metabolism in gut.

Mech of action:
5-fluoruracil is a pro-drug that is convered inot active metabolites 5-FdUMP and 5-FdUTP. 5-FdUMP inhibits thymidylate synthetase (inhibits T production). and 5-FdUTP is incorporated into RNA and interferes with RNA function.

Therapeutic use:

  • In combination therapy for breast, colorectal, gastric, heand & neck, cervical and pancreatic cancer.
  • basal cell carcinomas (topical use)

Toxicity:
anorexia and nausea
mucosal ulcerations, stomatitis and diarrhea
myleosuppression
HAND AND FOOT SYNDROME (sensitivity on palms and soles, erythema
CARDIAC TOXICITY (acute chest pain)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Cytarabine (AraC, Depocyt)

A

Antimetabolite
Class: Pyramidine analog

Mech of Action:
Ara-C converted by deoxycytidine kinase to Ara-CMP –> Ara-CTP; Competes with dCTP and is incorporated into transcribed DNA, terminates DNA synthesis as Ara-CTP

Therapeutics:
AML (most effective treatment), ALL, and blast phase CML

Toxicity:
SEVERE Meylosuppression
GI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Gemcitabine (dFdC, Gemzar)

A

Antimetabolite
Class: Pyramidine analog

Mech of Action:
Converted to active metabolites: dFdCDP inhibits ribonucleotide reductase (lowers deoxyribonucleotide); dFdCTP incorporates into DNA, terminating DNA synthesis

Therapeutics
Pancreatic cancer
effective against non-small cell lung cancer, ovarian, bladder, esophageal, and head and neck cancer

Toxicity:
Myleosuppression
FLU LIKE SYMPTOMS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

6-Mercaptopurine (Purinethol)

A

Antimetabolite
Class: Purine analog

Mech of Action:
9MP is a Prodrug that is metabolized by hypoxanthine-guanine phosphoribosyl transferase (HGPRT) to 6-thioinosinic acid (TIMP)
TIMP:
1. inhibits first step of de novo purine base synthesis
and the formation of AMP and xanthinylic acid from inosinic acid.
2. TIMP is converted to thio-guanine ribonucleotides, inhibiting DNA and RNA synthesis

Therapeutics:
Maintain remission in acute ALL

Toxicity:
myelosuppression
HEPATOTOXICITY IN PROLONGED USE

Resistance:

  • reduced metabolism of 6-MP to TIMP due to reduced expression of HGPRT
  • Decreased drug transport
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What are DNA Intercalating Agents?

A

Derived from strain of soil Streptomyces.

Mech of action:
Bind DNA through intercalation between specific bases, blocking DNA, RNA or both synthesis; cause DNA strands to break and interfere with cell replication; CCNS

Drugs: 
Dactinomycin (Actinomycin D, Cosmegan)
Daunorubicin (Cerubidine)
Idarubicin (Idamycin)
Doxorubicin (Adriamicin, Doxil)
Epirubicin (Ellence)
Bleomycin (Blenoxane)
28
Q

Dactinomycin (Actinomycin D, Cosmegan)

A

DNA Intercalating Agent
Class: none.

Mech of action:
Intercalates G-C base pairs of DNA, interfering with DNA-dependant RNA polymerase; also causes single strand DNA breaks

Therapeutic:
Pediatric tumors (Wilms’ tumor, rhabdomyosarcoma Ewing’s sarcoma);
choriocarcinoma in women

Toxicity:
Anorexia, nausea, vomiting (GI)
Severe HEMATOPOETIC SUPPRESSION WITH PANCYTOPENIA

29
Q

Daunorubicin (Cerubidine)
Idarubicin (Idamycin)
Doxorubicin (Adriamicin, Doxil)
Epirubicin (Ellence)

A

DNA Intercalating Agent
Class: Anthracyclines

Mech of action:
Intercalate between DNA base pairs and donates electrons to O2 to form superoxide; superoxide reacts with itself to form H2O2 –> cleaved in the presence of Fe to form OH radical, which cleaves DNA

Therapeutics:
Daunorubicin and Idarubicin: AML
Doxorubicin: Broad use, includes: sarcomas, breast and lung carcinomas, and malignant lymphomas
Epirubicin: Metastatic breast cancer and gastric cancer

Toxicity:
-IRREVERSABLE DOSE-LIMITING CARDIOTOXICITY
(NB: dexrazoxane is an iron chelating agend that blocks formation of free radicals and protects against cardiotoxicity)
-myelosuppression
-GI

30
Q

Bleomycin

A

DNA Intercalating Agent
Class: none.

Mech of action:
Acts in G2 phase of cell cycle. Binds to DNA, producing single strand and double strand DNA breaks.

Therapeutic uses:

  • Combination therapy for testicular tumors or Hodgkin’s disease
  • squamous cell carcinomas and lymphomas

Tocixity:
NB: MINIMALLY myleo- and immunosuppresive
PULMONARY FIBROSIS
CUTANEOUS (hyperpigmentation, hyperkeratosis, erythema)
HYPERTHERMIA
headache,
GI

31
Q

What are Mircotubule Inhibitors?

A

Mech of Action:
Inhibit mitosis and cause metaphase arrest by interfering with microtubule function (tubulin (de)polymerization); CCS

Drugs: 
Vinblastine (Velban)
Vincristine (Oncovin)
Paclitaxel (Taxol, Abraxane)
Docetaxel (Taxotere)
32
Q

Vinblastine

A

Microtubule Inhibitor
Class: Vinca alkaloids

Mech of Action:
Block tubulin polymerization into microtubules

Therapeutics:
Metastatic testicular tumors (with bleomycin, cisplatin); component of ABVD used for Hodgkin’s disease

Toxicity:
myleosuppression
GI

33
Q

Vincristine

A

Microtubule Inhibitor
Class: Vinca alkaloids

Mech of Action:
Block tubulin polymerization into microtubules

Therapeutics:
Childhood ALL (with glucocorticoids);
Hodgkin’s and non-Hodgkin’s lymphomas

Toxicity:
DOSE-LIMITING NEUROTOXICITY (PERIPHERAL NEUROPATHY)
NB: low toxicity to bone marrow

34
Q

Paclitaxel and Docetaxel

A

Microtubule Inhibitor
Class: Taxanes

Mech of Action:
Block microtubule depolymerization into tubulin

Therapeutics:
P and D: Metastatic breast, ovarian, lung, and head and neck cancers
D: hormone-refactory prostate cancer

Toxicity:
PERIPHERAL NEUROPATHY
neutropenia
HYPERSENSITIVITY REACTIONS (rashes, bronchospasms, etc)

35
Q

What are Topoisomerase Inhibitors?

A

Mech of action:
Prevent the resealing of topo I (single strand DNA) and topo II (double strand DNA); CCS

Drugs:
Etoposide (Etopophos)
Teniposide (Vumon)
Irinotecan (Camptosar)
Topotecan (Hycamtin)
36
Q

Etoposide (Etopophos)

Teniposide (Vumon)

A

Topoisomerase Inhibitors
Class: Epipodophyllotoxins

Derived from Podophyllotoxin

Mech of Action:
Inhibits topoisomerase II

Therapeutics:
E: Testicular carcinoma, lung cancer, and non-Hodgkin’s lymphoma
T: ALL

Toxicity:
DOSE-LIMITING MYLEOSUPPRESSION
oral mucositis

37
Q

Irinotecan (Camptosar)

Topotecan (Hycamtin)

A

Topoisomerase Inhibitors
Class: Camptothecin analogs

Mech of action:
Inhibits topoisomerase I

Therapeutics:
I: Advanced colorectal cancer; lung, ovarian, cervical and brain tumors
T: Ovarian and small cell lung cancer

Toxicity:
SEVERE neutropenia,
SEVERE diarrhea

38
Q

Pemetrexed

A

Antimetabolite
Class: Folate analog

Mech of action:
Polyglutamate forms that inhibit THF-dependent enzymes (e.g., DHFR, TS); metabolized to polyglutamate forms that inhibit THF-dependent enzymes (e.g., DHFR, thymidylate synthase (TS))

Therapeutics:
Colon cancer, mesothelioma, non-small cell lung cancer, pancreatic cancer

39
Q

What are the hormones/ antagonists used as chemotherapies?

A

Glucocorticoids (lymphatic leukemias and lymphomas)
Selective estrogen-receptor modulators (SERMs) (breast cancer)
Aromatase inhibitors (prostate cancer)

40
Q

Tamoxifen (Soltamox)

A

Hormone treatment
Class: Selective estrogen-receptor modulators (SERMs)

Mech of action:
Competes with estradiol for binding to estrogen receptor

Therapeutics:
ER-positive breast cancer, or as adjuvant therapy following primary breast tumor excision;
NB: prevention of breast cancer in high-risk patients

Toxicity: 
Hot flashes
hair loss
GI
increased risk of ENDOMETRIAL CANCER
increased risk of THROMBOEMBOLIC EVENTS
41
Q

Fulvestrant (Faslodex)

A

Hormone treatment
Class: Selective estrogen-receptor downregulator (SERDs)

Mech of action:
Binds with much higher affinity (>100-fold) to estrogen receptor than tamoxifen, inhibiting dimerization, increasing degradation, and reducing overall ER levels

Therapeutics:
Posmenopausal women with ER-positive metastatic breast cancer

42
Q

Prednisone (Meticorten)

A

Hormone Treatment
Class:Glucocorticoid

Mech of Action:
Inhibit mitosis in lymphocytes

Therapeutics:
ALL; combination for Hodgkin’s, non-Hodkin’s, multiple myeloma, and CLL

43
Q

Dexamethasone (Decadron)

A

Hormone Treatment
Class: Glucocorticoids

Mech of Action:
Inhibit mitosis in lymphocytes

Therapeutics:
Reduces edema in brain and spinal cord tumors with radiation therapy

44
Q

Aminoglutethamide (Cytadren)

A

Hormone Treatment
Class: Aromatase inhibitors

Mech of action:
Inhibits function of aromatase

Therapeutics:
Relatively weak, used against breast cancer

45
Q

Anastrozole (Arimidex)

A

Hormone Treatment
Class: Aromatase inhibitors

Mech of action:
Inhibits function of aromatase

Therapeutics:
First-line for ER-positive breast cancer in postmenopausal women

46
Q

Letrozole (Femara)

A

Hormone Treatment
Class: Aromatase inhibitors

Mech of action:
Inhibits function of aromatase

Therapeutics:
ER-positive breast cancer in postmenopausal women

47
Q

Exemestane (Aromasin)

A

Hormone Treatment
Class: Aromatase inhibitors

Mech of Action:
Steroidal inhibitor of aromatase

Therapeutics:
ER-positive breast cancer in postmenopausal women

48
Q

Leuprolide (Lupron)

Goserelin (Zoladex)

A

Hormone treatment
Class: GnRH analogs

Mech of action:
Binds GnRH receptor; inhibits release of FSH & LH Androgen ablation therapy, along with AR blockers
GnRH analogs Binds GnRH receptor; inhibits release of FSH & LH

Therapeutics:
Androgen ablation therapy, along with AR blockers

49
Q

Flutamide (Eulexin)

Bicalutamide (Casodex)

A

Hormone treatment
Class: Nonsteroidal androgen-receptor blockers

Mech of action:
Competes with androgen for AR binding

Therapeutics:
Androgen ablation therapy, along with GnRH analogs

50
Q

Imatinib (Gleevac)

A

Tyrosine Kinase inhibitor

Mech of action:
Inhibits Abl kinase by binding where ATP should go; also inhibits PDGFR and c-kit; metabolized by cytochrome P450

Therapeutics:
First line therapy for CML;
gastrointestinal tumor (GIST)

Toxicity:
minimal GI, myleosuppression, edema, muscle cramps and arthalgia

NB: given orally 1/day

Resistance:
mutations of BCR-ABL kinase
Unable to reach target protein if it binds to other proteins

51
Q

Gefitinib (Iressa)

A

Tyrosine Kinase inhibitor

Mech of Action:
Inhibit epidermal growth factor receptor (EGFR) tyrosine kinase

Therapeutics:
Non-small lung cancer

52
Q

Erlotinib (Tarceva)

A

Tyrosine Kinase inhibitor

Mech of action:
Inhibit epidermal growth factor receptor (EGFR) tyrosine kinase

Therapeutics:
Non-small lung cancer

53
Q

Nilotinib (Tasigna)

A

Tyrosine Kinase inhibitor

Mech of action:
Inhibits Abl kinase

Therapeutics:
Imatinib-resistant CML

Toxicity:
Myleosuppression
PROLONGED Q/T
HEPATOTOXICITY
electrolyte imbalances
54
Q

Dasatinib (Sprycel)

A

Tyrosine Kinase inhibitor

Mech of action
Inhibits Abl & Src kinases

Therapeutics:
Imatinib-resistant CML

Toxicity:
Myleosuppression
GI
fluid retention
PULMONARY ARTERIAL HYPERTENSION
55
Q

Rituximab (Rituxan)

A

Monoclonal antibody

Mech of Action:
CD20 B-cell antibody that can directly activate apoptosis, activate complement, or activate cell-mediated cytotoxicity (e.g., T cells, NK cells)

Therapeutics:
Non-Hodgkin’s lymphomas

Toxicity:
IMPORTANT: Infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML)

skin reactions, joint pain, irregular heartbeat

NB: must monitor patients carefully

56
Q

Trastuzumab (Herceptin)

A

Monoclonal antibody

Mech of Action:
Unknown HER2/neu (ErbB2) receptor antibody mechanism (enhanced receptor endocytosis or blocking homo- or heterodimerization)

Therapeutics:
HER2/neu-overexpressing metastatic breast cancer

Toxicity:
HYPERSENSITIVITY
VENTRICULAR DYSFUNCTION

NB: Usually combined with taxanes; enhances doxorubicin cardiotoxicity

57
Q

Cetuximab (Erbitux)

A

Monoclonal antibody

Mech of Action:
antibody agains EGFR1 (ErbB1)

Therapeutics:
EGFR-positive metastatic colorectal cancer

Toxicity: 
ALLERGIC REACTIONS
SUDDEN CARDIAC DEATH
RENAL FAILURE
ELECTROLYTE ABNORMALITIES
dermatologic problems 
infections
flu like symptoms, 
interstitial pneumonitis
constipation
58
Q

Ipilimumab (Yervoy)

A

Human monoclonal antibody

Mech of action:
Cytotoxic T-Lymphocyte Antigen 4 inhibitor;stimulates immune system

Therapeutics:
Melanoma

59
Q

Vemurafenib (Zelboraf)

A

Serine/threonine kinase inhibitor

Mech of action:
Inhibits oncogenic BRAF kinase

Therapeutics:
Unresectable Stage III and IV or metastatic melanomas w/BRAF mutations

Toxicity:
IMPORTANT: Arthralgia, fatigue, photosensitivity, nausea, alopecia, diarrhea, QT prolongation

other: Cutaneous squamous cell carcinoma, keratoacanthoma, new primary cutaneous melanoma

60
Q

Dabrafenib (Tafinlar)

A

Serine/threonine kinase inhibitor

Mech of action:
Inhibits oncogenic BRAF kinase

Therapeutics:
Unresectable Stage III and IV or metastatic melanomas w/BRAF mutations

Toxicity:
IMPORTANT: Serious febrile drug reactions, uveitis and iritis, hyperglycemia, hyperkeratosis

OTHER: Higher risk of Cutaneous squamous cell carcinoma, keratoacanthoma, new primary cutaneous melanoma

NB: May cause male infertility

61
Q

Trametinib (Mekinist)

A

Inhibits MEK

Therapeutics:
Unresectable Stage III and IV or metastatic melanomas w/BRAF mutations

Toxicity:
IMPORTANT: Cardiomyopathy, retinal disorders, interstitial lung disease, serious skin toxicities

OTHER:
Rash, diarrhea, stomatitis, hypertension, pruritis

NB: May cause female infertility

62
Q

Hydroxyurea (Hydrea)

A

Mech of action:
Inhibits ribonucleoside diphosphate reductase

Therapeutics:
CML (replaced by Imatinib), polycythemia vera, essential thrombocythemia; treatment for sickle cell disease (increases Hb-F)

63
Q

Retinoids

A

Mech of action:
ATRA induces terminal differentiation in malignant immature promyelocytes, which subsequently apoptose

Therapeutics:
APL

Toxicity:
IMPORTANT: “Leukocyte Activation Syndrome” (LAS), an increase in WBCs (fever, weight gain, respiratory distress, serosal effusion, renal failure)

NB: Combined w/anthracyclines; corticosteroids used to block “LAS”

64
Q

Arsenic Trioxide (Trisenox)

A

Therapeutics:

Relapsed APL

65
Q

Thalidomide (Thalomid)

A

Therapeutics: Multiple myeloma and myelodysplastic syndromes

66
Q

Interferons

A

Therapeutics:

Hairy-cell leukemia, CML, and AIDS-related Kaposi’s sarcoma